GLOBAL HEALTH | GLOBAL PARTNERSHIPS | GLOBAL IMPACT

Research

Photo for EPIC STEMI

EPIC STEMI

Official Title

Effects of Acute, Rapid Lowering of Low Density Lipoprotein (LDL) Cholesterol with Alirocumab in Patients with STEMI Undergoing Primary PCI

Status

Ongoing

Overview

Evaluating the effects of acute treatment with a PCSK9 inhibitor (alirocumab) versus placebo on low-density lipoprotein (LDL) in 100 high-risk patients presenting with STEMI and referred for primary PCI. The hypothesis is that, in patients with STEMI undergoing primary PCI, rapid lowering of LDL cholesterol with a PCSK9 Inhibitor (alirocumab) initiated in the acute setting pre-PCI, will favourably affect LDL cholesterol concentrations compared with placebo.

Study Design

A randomized, double-blind, placebo controlled parallel group clinical trial

Primary Endpoint

To determine the effect of acute, rapid lowering of LDL cholesterol with alirocumab added to high dose statin therapy in patients with STEMI undergoing primary PCI.

Number of Patients

100

Number of Sites

1

Number of Countries

1

Study Period

2018-2019

Principal Investigator

Shamir Mehta, Eva Lonn, Gui Paré, Matthew McQueen

Program Manager

Brandi Meeks

Research Coordinator

Helen Nguyen